American journal of cardiovascular disease最新文献

{"title":"Clinical characteristics, medication, and outcomes of spontaneous coronary artery dissection patients with an initial strategy of percutaneous coronary intervention or conservative therapy.","authors":"Kang-Zheng Yuan, Jian Wang, Min Lu, Fang-Mei Liu, Min Deng, Sai-Nan Chang, Qing-Chi Liao","doi":"10.62347/FDZD1794","DOIUrl":"10.62347/FDZD1794","url":null,"abstract":"<p><strong>Objectives: </strong>Spontaneous Coronary Artery Dissection (SCAD) is a rare non-obstructive acute coronary syndrome. Although previously characterized by a lack of consensus on optimal management, treatment guidelines for SCAD have now been established to inform clinical practice. However, long-term follow-up data specifically for SCAD patients in China are lacking. The present study aimed to assess the clinical and angiographic outcomes of a Chinese cohort managed with initial Percutaneous Coronary Intervention (PCI) or conservative therapy.</p><p><strong>Methods: </strong>The study enrolled 33 patients from the Northern Jiangsu People's Hospital, affiliated with Yangzhou University, whose initial diagnosis of SCAD was made from April 1, 2014 to June 30, 2020. The study recommended a follow-up coronary angiography for all patients 6 months after the initial onset. Clinical characteristics, angiographic findings, initial treatment strategies, discharge medications, and outcomes were recorded for all patients.</p><p><strong>Results: </strong>Among the 33 patients with SCAD (mean age 51.9±9.7 years, 69.7% female), myocardial infarction was the predominant presentation (75.7%), with Non-ST-Segment Elevation Myocardial Infarction (NSTEMI) accounting for the majority of cases (51.5%). The left anterior descending artery (LAD) was the most frequently involved vessel (63.6%). According to the Saw classification, type 2b lesions predominated (65.7%). Compared to the conservative group, patients in the PCI group presented with a significantly higher degree of stenosis [100% (IQR, 98-100) vs. 70% (IQR, 70-80), P < 0.001] and a higher prevalence of baseline TIMI 0-1 flow (81.8% vs. 0%, P < 0.001). PCI was technically successful (TIMI 2-3 flow post-procedure) in all patients. During the initial hospitalization, the overall MACE rate was 9.1% (3/33). Over a median follow-up of 27.5 months (IQR, 15.3-51.3), the MACE rate was 9.4% (3/32), including one cardiac death. Recurrent Spontaneous Coronary Artery Dissection (R-SCAD) was confirmed in 3 patients (9.4%). No significant difference was observed in MACE-free survival between the PCI and conservative groups (59.3% vs. 85.7%, P=0.126). Follow-up coronary angiography (CAG) performed in 16 patients (50%) demonstrated angiographic healing in 15 patients (93.8%). Notably, 2 of the 3 patients who experienced late MACE had previously demonstrated complete lesion healing on 6-month follow-up CAG. Patients who underwent 6-month follow-up CAG exhibited a numerically lower MACE-free survival rate compared to those who did not, although this difference did not reach statistical significance (62.9% vs. 100.0%, P=0.10).</p><p><strong>Conclusion: </strong>This study reported that the outcomes of patients subjected to an initial conservative strategy were not inferior as compared to those treated with PCI. In patients who underwent follow-up CAG, healing was commonly observed. Therefore, guiding antiplatelet thera","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"16 3","pages":"142-155"},"PeriodicalIF":1.4,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13389454/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148560495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effectiveness of hydrotherapy on quality of life and exercise capacity in patients with cardiac diseases: a scoping review.","authors":"Alaa A Khushhal, Mohamed S Alayat, Ashraf Am Abdelaal","doi":"10.62347/VGMT1935","DOIUrl":"10.62347/VGMT1935","url":null,"abstract":"<p><p>Although hydrotherapy is an alternative treatment for people with heart conditions, it is still unknown how hydrotherapy would affect these patients' quality of life and ability to exercise. The aim of this review is to investigate the impact of hydrotherapy on heart disease patients. A search of the databases PubMed, the Physiotherapy Evidence Database (PEDro), EBSCO, Scopus, and Google Scholar was conducted to identify randomized controlled trials (RCTs) examining how hydrotherapy affects people with heart conditions. The PEDro scale was used to evaluate the methodological quality of the research for bias risk. This scoping review comprised eleven studies with a total of 245 cardiac patients. Hydrotherapy reduced heart rate, mean arterial pressure, systemic vascular resistance, and cardiac index in patients with chronic heart failure and increased exercise tolerance, peak power output, and total body strength in male patients with coronary artery disease. It also improved work rate, cardiac output, stroke volume, exercise and walking capacity, and peak oxygen uptake. The risk of bias assessment revealed that one study was excellent quality, eight studies were good quality, and two were poor quality. Hydrotherapy is an effective physical therapy modality for the rehabilitation of patients with cardiac diseases. However, further, larger studies with less heterogeneity are required due to the low-quality studies and low-quality evidence to confirm the findings and elucidate the underlying mechanisms of hydrotherapy in cardiac patients.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"16 3","pages":"177-184"},"PeriodicalIF":1.4,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13389449/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148560457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protective effect of overweight status in aortic valve surgery: revisiting the obesity paradox.","authors":"Harrison Feerst, Mehrtash Hashemzadeh, Mohammad Reza Movahed","doi":"10.62347/LTPQ4636","DOIUrl":"10.62347/LTPQ4636","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the relationship between body mass index (BMI) and postoperative mortality in patients undergoing aortic valve surgery, with an emphasis on exploring the presence and limits of the \"obesity paradox\", the phenomenon wherein overweight and mildly obese patients may experience lower mortality despite obesity's general association with adverse health outcomes.</p><p><strong>Methods: </strong>The Nationwide Inpatient Sample (NIS) database was used to obtain data from adult patients who underwent aortic valve surgery between 2016 and 2020. BMI categories, as well as comorbidities, were identified using ICD-10 codes. Mortality rates across BMI categories were compared, and multivariate analysis was performed to adjust for comorbid conditions. This is a retrospective observational study.</p><p><strong>Results: </strong>We found 301,250 adult patients who underwent aortic valve surgery. Normal weight patients (n=226,490) had a mortality rate of 3.79%. Overweight (n=2,555) and obese (n=46,320) patients demonstrated significantly lower mortality rates of 1.17% (OR=0.30, 95% CI: 0.14-0.66; P=0.003) and 2.43% (OR=0.63, 95% CI: 0.55-0.73; P<0.001), respectively. Cachectic patients (n=835) had the highest mortality rate at 14.97% (OR=4.47, 95% CI: 2.87-6.96; P<0.001). Morbidly obese patients (n=25,450) had a mortality rate of 4.13%, which was not significantly different from normal-weight patients (OR=1.09, 95% CI: 0.94-1.26; P=0.23). These trends and statistical significance remained after multivariate logistic regression, accounting for demographics and comorbidities.</p><p><strong>Conclusions: </strong>The partial obesity paradox is true in patients undergoing aortic valve surgery, with the lowest mortality occurring in overweight patients, followed by obese patients, and with cachexia having the highest mortality out of all groups.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"16 3","pages":"185-193"},"PeriodicalIF":1.4,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13389453/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148560501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective real-world study on effectiveness and safety of sacubitril/valsartan in Indian patients with heart failure.","authors":"Ashwani Mehta, Kapil Dev Mehta, Komal Mangaonkar","doi":"10.62347/RYQH3714","DOIUrl":"10.62347/RYQH3714","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the clinical, biochemical, and functional outcomes of sacubitril/valsartan therapy in Indian patients with heart Failure (HF) with reduced ejection fraction (HFrEF) in routine practice.</p><p><strong>Methods: </strong>We conducted a retrospective, single-centre, observational study at The Heart Clinic, New Delhi, India. Adult patients (≥18 years) with the New York Heart Association (NYHA) class II-IV HF who were newly initiated on sacubitril/valsartan and had ≥12 months of follow-up were included in the study. Clinical, echocardiographic, and biochemical data were extracted from the electronic medical records. The primary outcomes at 12 months were changes in left ventricular ejection fraction (LVEF), NYHA classification, N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, estimated glomerular filtration rate (eGFR), and the number of patients receiving the maximum dose of sacubitril/valsartan. The secondary outcomes were cardiovascular and all-cause mortality.</p><p><strong>Results: </strong>A total of 300 patients were analyzed (mean age, 61.3 years; 69.7% male). Hypertension (266 patients, 88.7%), diabetes (163 patients, 54.3%), and chronic kidney disease (153 patients, 51%) were the most frequent comorbidities. At 12 months, the mean LVEF increased significantly from 29.57% to 34.66% (absolute gain of 5.09%, <i>P</i><0.0001). A significant improvement in functional ability was observed, with 282 patients (94%) classified as NYHA class II at 12 months compared with 22 patients (7.3%) at baseline (<i>P</i><0.0001), and the NT-proBNP levels decreased from 2344.5 ± 1951.8 pg/mL to 564 ± 410.3 pg/mL (<i>P</i><0.0001). Renal function remained stable (mean change in eGFR +2.01 mL/min/1.73 m², <i>P</i>=0.088). Over half of the cohort (52.3%) achieved a target dose of 200 mg twice daily. No cardiovascular or all-cause deaths were observed.</p><p><strong>Conclusion: </strong>In this real-world Indian cohort, sacubitril/valsartan was associated with significant improvements in systolic function, functional class, and NT-proBNP levels, with preserved renal function and good tolerability. These findings support the use of sacubitril/valsartan as a cornerstone therapy for HFrEF management in routine clinical practice.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"16 3","pages":"194-204"},"PeriodicalIF":1.4,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13389447/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148560498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of reperfusion delay with inflammatory markers and coronary flow impairment assessed by corrected TIMI frame count in STEMI patients undergoing primary PCI: a cohort study.","authors":"Reza Arian Nia, Morteza Safi, Mohammad Saeed Soleimani Meigoli, Mohammad Hasan Namazi, Vajihe Kooshamoghadam, Kiarash Fadaeihaghi, Sepita Taghipour, Parsa Mostaghimi Motlagh, Zahra Sadat Shayegh, Shayan Ghanouni, Mahan Safari, Aida Azhdarimoghaddam, Mahsa Bahmanpour, Farbod Khosravi, Nadia Pourmohammadi, Sepehr Ramezanipour, Sepehr Mahmoodi Azar, Kamyar Khorsand","doi":"10.62347/AGMN7983","DOIUrl":"10.62347/AGMN7983","url":null,"abstract":"<p><strong>Background: </strong>Timely reperfusion remains central to the management of ST-segment elevation myocardial infarction (STEMI). In addition to limiting infarct size, delays in reperfusion may intensify systemic inflammation and contribute to impaired coronary microvascular flow, even when epicardial recanalization appears angiographically successful. This study examined whether reperfusion delay is associated with inflammatory markers at admission and impaired coronary flow measured by corrected TIMI frame count (CTFC) in patients with STEMI treated with primary PCI.</p><p><strong>Methods: </strong>We conducted a single-center observational cohort study including 104 consecutive patients with STEMI who underwent primary percutaneous coronary intervention (PPCI).Reperfusion delay was defined as symptom-to-balloon time and was grouped into four categories (< 2, 2-4, 4-6, and > 6 hours). Inflammatory markers, including erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), were measured at admission and after PPCI. Coronary flow was quantitatively assessed using the corrected TIMI frame count (CTFC). Associations between reperfusion delay, inflammatory markers, and CTFC were evaluated.</p><p><strong>Results: </strong>CTFC values increased progressively with longer reperfusion delay, indicating worsening coronary flow (P < 0.05). Admission ESR increased significantly with longer symptom-to-balloon time (P < 0.05), and higher CRP categories were more frequently observed among patients with delayed reperfusion (P < 0.05). Higher ESR and CRP levels at admission were also associated with increased CTFC values. Post-procedural ESR and CRP levels, however, showed no significant association with reperfusion delay or CTFC (P > 0.05). Higher ESR and CRP levels at admission were also linked with increased CTFC values. Post-procedural ESR and CRP levels, however, showed no significant association with reperfusion delay or CTFC.</p><p><strong>Conclusions: </strong>In patients with STEMI undergoing primary PCI, delayed reperfusion is associated with increased inflammatory burden at presentation and impaired coronary flow as assessed by corrected TIMI frame count. Taken together, these findings suggest that inflammatory activation during prolonged ischemia may contribute to impaired coronary flow and highlight the continued importance of minimizing reperfusion delay.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"16 3","pages":"156-166"},"PeriodicalIF":1.4,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13389452/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148560410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between visceral adiposity index and hypertension in reproductive-aged women: evidence from NHANES 1999-2023.","authors":"Ying Peng, Xi-Dai Long","doi":"10.62347/UEEQ7921","DOIUrl":"10.62347/UEEQ7921","url":null,"abstract":"<p><strong>Objectives: </strong>The visceral adiposity index (VAI), an indicator of visceral fat accumulation and dysfunction, has been proposed as a potential marker for cardiometabolic risk. However, its association with hypertension in women of reproductive age remains unclear. Therefore, this study aims to investigate the association between VAI and the prevalence of hypertension in this specific population.</p><p><strong>Methods: </strong>This cross-sectional study analyzed data from 2,571 women of reproductive age using the National Health and Nutrition Examination Survey (NHANES) database. Weighted multivariable logistic regression models were used to examine the relationship between VAI and hypertension, adjusting for potential confounders. Restricted cubic spline (RCS) modeling and two-piecewise linear regression were applied to evaluate the dose-response and threshold effects. Subgroup and interaction analyses were conducted across demographic and lifestyle factors.</p><p><strong>Results: </strong>VAI was significantly and positively associated with the prevalence of hypertension in women of reproductive age (OR = 1.18, 95% CI: 1.08-1.29; <i>P</i> < 0.001). Smooth curve fitting revealed a nonlinear positive relationship (nonlinear <i>P</i> < 0.001), with a notable inflection point at VAI = 1.285. Below this threshold, the odds of hypertension increased sharply (OR = 4.48; 95% CI: 2.25-8.91; P < 0.001), while above it, the odds increased modestly (OR = 1.07; 95% CI: 1.02-1.13; <i>P</i> = 0.008). Subgroup analyses confirmed the robustness of this association across most strata. A significant interaction was found in the racial/ethnic subgroup (<i>P</i> for interaction = 0.017), suggesting varying strength of association among different racial groups.</p><p><strong>Conclusion: </strong>VAI is independently and nonlinearly associated with increased odds of hypertension in women of reproductive age, demonstrating a distinct threshold effect. These findings suggest that VAI may serve as a potential observational marker for evaluating cardiovascular risk in this population. Maintaining VAI below the 1.285 threshold could be considered in early cardiovascular prevention strategies.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"16 3","pages":"167-176"},"PeriodicalIF":1.4,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13389450/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148560390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing cardiac tumor diagnosis: evaluating ¹⁸F-FDG PET/CT against traditional imaging methods.","authors":"Jalal Kargar, Farshad Riahi, Reza Gerami","doi":"10.62347/KEGM5869","DOIUrl":"10.62347/KEGM5869","url":null,"abstract":"<p><strong>Background: </strong>Cardiac tumors are rare but clinically significant lesions requiring prompt and accurate diagnosis. While echocardiography remains the first-line imaging modality, it is limited by its inability to characterize tissue. Cardiovascular magnetic resonance imaging (CMR) and cardiac computed tomography (CT) offer superior anatomical detail but cannot reliably differentiate benign from malignant tumors. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) provides metabolic information that may overcome these limitations.</p><p><strong>Methods: </strong>A systematic scoping review was conducted following a structured literature search covering January 2019 to September 2025. After screening 192 articles and applying predefined inclusion and exclusion criteria, 7 retrospective studies enrolling a total of 381 adult patients with newly diagnosed cardiac masses who underwent ¹⁸F-FDG PET/CT were included.</p><p><strong>Results: </strong>Across all included studies, ¹⁸F-FDG PET/CT demonstrated high diagnostic accuracy in differentiating benign from malignant cardiac and pericardial masses. Key quantitative metabolic parameters consistently outperformed traditional imaging modalities. Reported sensitivity and specificity ranged from 92-100% and 88-93%, respectively. In one study, ¹⁸F-FDG PET/CT achieved a 100% decision-making rate and the highest area under the curve (AUC) of 0.94 compared to transthoracic echocardiography, CT, and CMR. SUVmax also emerged as an independent predictor of survival.</p><p><strong>Conclusion: </strong>¹⁸F-FDG PET/CT plays a significant diagnostic and prognostic role in evaluating cardiac tumors, offering metabolic insights that complement conventional anatomical imaging. It should be incorporated as a key adjunct in the multimodality work-up of suspected cardiac masses, particularly when malignancy is suspected or biopsy is not feasible.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"16 2","pages":"80-91"},"PeriodicalIF":1.4,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13195258/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148013044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mid-life antihypertensive initiation and incident dementia: a machine learning-weighted target trial emulation in the health and retirement study.","authors":"Sajjad Hajihosseini, Reza Khademi, Anita Fatehi, Behnoosh Taghvaei, Yousef Dowlatabadi, Serve Mamkhezri, Taher Fanihagh, Mohaddeseh Belbasi, Maryam Gholizadeh, Atiye Rashidi, Danyal Yarahmadi, Saeid Najafi","doi":"10.62347/KEXT8146","DOIUrl":"10.62347/KEXT8146","url":null,"abstract":"<p><strong>Background: </strong>Mid-life hypertension is a treatable vascular risk for dementia, yet trial evidence on whether starting antihypertensives in middle age lowers late-life dementia remains mixed. This study aimed to emulate a randomized trial to estimate whether initiating antihypertensive therapy at mid-life reduces subsequent dementia risk.</p><p><strong>Methods: </strong>We emulated a randomized target trial of antihypertensive initiation using Health and Retirement Study data (2002-2020; 18-year follow-up). Eligible adults aged 45-65 with incident hypertension and dementia-free at baseline (n = 2,491) were classified in 2002 as antihypertensive treatment initiators or non-initiators. Inverse probability weights combined (I) a Firth-penalized logistic model for treatment initiation and (II) biennial censoring models; weighted Cox regression estimated hazard ratios (HRs) for incident dementia. To probe model dependence, we re-estimated treatment weights with a Super Learner ensemble and repeated all analyses.</p><p><strong>Results: </strong>Groups differed on several baseline covariates, but weighting brought every standardized mean difference to <0.10. During follow-up, cumulative dementia incidence reached 15% in non-initiators and 13% in initiators. The intention-to-treat risk ratio (RR) was 0.89 (95% confidence interval [CI], 0.57-1.62); biennial RRs were likewise close to the null. Re-estimating treatment weights with a Super Learner ensemble yielded comparable covariate balance and a year-18 RR of 1.05 (0.74-1.70), essentially reproducing the primary result. Analyses accounting for competing risks of death or dropout did not materially change the estimates.</p><p><strong>Conclusions: </strong>In this nationally representative cohort, starting antihypertensive therapy in mid-life did not meaningfully change dementia risk across 18 years. Agreement between conventional and machine-learning propensity approaches makes a large protective or harmful effect unlikely and underscores the need to explore additional strategies for dementia prevention beyond routine blood pressure pharmacotherapy.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"16 2","pages":"109-124"},"PeriodicalIF":1.4,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13195260/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148013136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between the triglyceride-glucose index and non-alcoholic fatty liver disease among individuals with atrial fibrillation.","authors":"Tao Li, Zihang Zhang, Xianrui Li, Muhammad Arslan Ul Hassan, Xin Yu, Chunxia Li, Ruilian Ma, Yan Ma, Zhen Yang","doi":"10.62347/MPGL1199","DOIUrl":"10.62347/MPGL1199","url":null,"abstract":"<p><strong>Background: </strong>The triglyceride-glucose (TyG) index serves as a reliable surrogate marker of insulin resistance. Accumulating evidence links an elevated TyG index to increased cardiovascular risk, but its relationship with nonalcoholic fatty liver disease (NAFLD) in atrial fibrillation (AF) patients remains underexplored. This study aimed to investigate the association between the TyG index and NAFLD incidence among AF patients.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of 298 AF patients from a single tertiary care center. NAFLD was diagnosed via hepatic ultrasonography after secondary causes were excluded. TyG index was calculated as ln [fasting triglycerides (mg/dL) × fasting glucose (mg/dL)/2]. Logistic regression models were employed to assess the independent association between the TyG index and NAFLD.</p><p><strong>Results: </strong>The NAFLD prevalence was 27.9% (83/298). Patients with NAFLD presented significantly greater TyG index values (8.90 ± 0.05 vs. 8.62 ± 0.04; P < 0.001). After multivariable adjustment, each 1-unit increment in the TyG index independently predicted NAFLD (OR 2.194, 95% CI 1.149-4.190; P = 0.017). Receiver operating characteristic curve analysis demonstrated moderate discriminative ability (AUC 0.667, 95% CI 0.601-0.732). A dose-response relationship was observed (P for trend < 0.001), with NAFLD incidence increasing progressively across TyG tertiles (12.87%, 29.81%, and 40.82%).</p><p><strong>Conclusions: </strong>An elevated TyG index is an independent risk factor for NAFLD in AF patients, suggesting a shared metabolic pathophysiology between insulin resistance, hepatic steatosis, and cardiac arrhythmia. The TyG index may serve as a readily available tool for NAFLD risk stratification in this high-risk population.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"16 2","pages":"101-108"},"PeriodicalIF":1.4,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13195261/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148013095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between inflammatory diseases and connective tissue disorders with atrial fibrillation/flutter.","authors":"Tala Araghi, Mehrtash Hashemzadeh, Mohammad Reza Movahed","doi":"10.62347/HKSK4068","DOIUrl":"10.62347/HKSK4068","url":null,"abstract":"<p><strong>Background: </strong>The role of inflammatory disease in the occurrence of atrial fibrillation/flutter (AF/AFL) is not well studied.</p><p><strong>Objective: </strong>The goal of this study was to evaluate any association between inflammatory and autoimmune disorders with the occurrences of AF/AFL using a large database.</p><p><strong>Methods: </strong>Using the Nationwide Inpatient Sample (NIS) database and ICD-10 codes for AF/AFL and several inflammatory diseases for the years 2016-2020, we evaluated the above association.</p><p><strong>Results: </strong>A total of 23,037,013 patients were identified with a diagnosis of AF/AFL. The following diseases were independently associated with the presence of AF/AFL despite adjustment for age, demographics, and traditional risk factors: rheumatoid arthritis: OR: 1.05, CI 1.04-1.06, P<0.001, systemic sclerosis OR: 1.31, CI 1.26-1.36, P<0.001, systemic connective tissue disorders: OR: 1.07, CI 1.05-1.08, P<0.001, antiphospholipid syndrome: OR: 1.36, CI: 1.31-1.42, P<001, systemic lupus erythematosus: OR: 1.15, CI: 1.13-1.17, P<0.001 and Raynaud's syndrome: OR: 1.1, CI: 1.07-1.13, P<0.001. Ankylosing spondylitis was not found to be associated with AF/AFL.</p><p><strong>Conclusion: </strong>Using a large inpatient database, we found that some common inflammatory diseases and connective tissue disorders are independently associated with the presence of AF/AFL. Our findings are hypothesis-generating, requiring confirmation in prospective controlled trials.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"16 2","pages":"92-100"},"PeriodicalIF":1.4,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13195259/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148013160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}